Dupilumab-associated sezary syndrome
Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for...
Saved in:
Main Authors: | Austin Hamp (Author), Jamie Hanson (Author), Albert Alhatem (Author), Robert A Schwartz (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dupilumab aggravates Sézary syndrome: The importance of accurate pathological diagnosis
by: Yoko Homma, et al.
Published: (2023) -
A Case of Sézary Syndrome in a Patient Treated with Dupilumab for Atopic Dermatitis
by: Kaito Muramatsu, et al.
Published: (2024) -
Alemtuzumab in refractory Sézary syndrome
by: Carmen María Alcántara Reifs, et al.
Published: (2016) -
A rare association of bullous pemphigoid with mycosis fungoides and Sézary syndrome
by: Andjela Egger, BS, et al.
Published: (2020) -
Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario
by: José Antonio Sanches, et al.
Published: (2021)